Monsanto intends to sell Posilac business
August 07, 2008
by Keith Nunes
ST. LOUIS — The Monsanto Co. is in the process of divesting its Posilac bovine somatotropin business unit. Posilac is a treatment dairymen may use to increase milk production in their herd. It also has been the center of controversy for some time.
"While Posilac is a strong product for the business, we believe repositioning the business with a strategic owner will allow Monsanto to focus on the growth of its core seeds and traits business while ensure that loyal dairy farmers continue to receive the value of Posilac in their operations," said Carl Casale, executive vice-president of strategy and operations for Monsanto.
Several major milk processors have banned their producers from using the treatment. In addition, companies like Ben & Jerry’s Homemade Holdings, Inc., and Kraft Foods Inc., market products as being free of the supplement.